Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

BACKGROUND: This open-label phase i study with an accelerated titration design was performed to determine the maximum tolerated dose of BI 2536, a potent, highly selective small-molecule polo-like kinase 1 (Plk1) inhibitor. METHODS: Patients with advanced solid tumours received a single 60-minute in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Frost, A., Mross, K., Steinbild, S., Hedbom, S., Unger, C., Kaiser, R., Trommeshauser, D., Munzert, G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Multimed Inc. 2012
Schlagworte:
Updates and Developments in Oncology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267594/
https://ncbi.nlm.nih.gov/pubmed/22328845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.19.866
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge